BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 11489795)

  • 21. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.
    Wiedswang G; Borgen E; Kåresen R; Kvalheim G; Nesland JM; Qvist H; Schlichting E; Sauer T; Janbu J; Harbitz T; Naume B
    J Clin Oncol; 2003 Sep; 21(18):3469-78. PubMed ID: 12972522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients.
    Domínguez G; Carballido J; Silva J; Silva JM; García JM; Menéndez J; Provencio M; España P; Bonilla F
    Clin Cancer Res; 2002 Apr; 8(4):980-5. PubMed ID: 11948103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracellular tumor DNA in plasma and overall survival in breast cancer patients.
    Garcia JM; Garcia V; Silva J; Peña C; Dominguez G; Sanchez A; Sanfrutos L; Provencio M; Millan I; Chaparro D; España P; Bonilla F
    Genes Chromosomes Cancer; 2006 Jul; 45(7):692-701. PubMed ID: 16607614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
    Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
    Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer.
    Bhargava V; Thor A; Deng G; Ljung BM; Moore DH; Waldman F; Benz C; Goodson W; Mayall B; Chew K
    Mod Pathol; 1994 Apr; 7(3):361-8. PubMed ID: 8058709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
    Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
    Broët P; Spyratos F; Romain S; Quillien V; Daver A; Ricolleau G; Rallet A; Toulas C; Asselain B
    Br J Cancer; 1999 May; 80(3-4):536-45. PubMed ID: 10408864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
    Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
    Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
    J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers.
    Wang JY; Hsieh JS; Chen CC; Tzou WS; Cheng TL; Chen FM; Huang TJ; Huang YS; Huang SY; Yang T; Lin SR
    J Surg Res; 2004 Aug; 120(2):242-8. PubMed ID: 15234219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
    Lopes A; Bezerra AL; Pinto CA; Serrano SV; de MellO CA; Villa LL
    J Urol; 2002 Jul; 168(1):81-6. PubMed ID: 12050497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer.
    Kato T; Kameoka S; Kimura T; Tanaka S; Nishikawa T; Kobayashi M
    Anticancer Res; 2002; 22(2B):1105-12. PubMed ID: 12168908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations.
    Silva JM; Dominguez G; Garcia JM; Gonzalez R; Villanueva MJ; Navarro F; Provencio M; San Martin S; España P; Bonilla F
    Cancer Res; 1999 Jul; 59(13):3251-6. PubMed ID: 10397273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.
    Wiedswang G; Borgen E; Kåresen R; Qvist H; Janbu J; Kvalheim G; Nesland JM; Naume B
    Clin Cancer Res; 2004 Aug; 10(16):5342-8. PubMed ID: 15328170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
    Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
    Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival.
    Tommiska J; Eerola H; Heinonen M; Salonen L; Kaare M; Tallila J; Ristimäki A; von Smitten K; Aittomäki K; Heikkilä P; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2005 Jul; 11(14):5098-103. PubMed ID: 16033823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.